Clinical Trial Update: Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ambrisentan plus tadalafil for portopulmonary hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Portopulmonary Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)
• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Ochsner Health System | Conditions: Portopulmonary Hypertension, Pulmonary Hypertension | Phase 4 | Status: WITHDRAWN